SCHEDULE 13G/A: EcoR1 Capital Reduces Stake in Immunome Inc. Below 5% Threshold

Sentiment:

Beneficial Ownership Statement Amendment 15 May 2025 6:04 PM

EcoR1 Capital, LLC and its affiliates have filed an amendment to their Schedule 13G, indicating a reduction in their beneficial ownership of Immunome Inc. common stock to 4.7%, falling below the 5% reporting threshold.

Worse than expectedThe reporting entities, EcoR1 Capital, LLC and Oleg Nodelman, have reduced their beneficial ownership in Immunome Inc. to 4.7% of the common stock, falling below the 5% threshold. EcoR1 Capital Fund Qualified, L.P. holds 4.4%. This indicates a reduction in their previously reported stake, as Schedule 13G is filed when ownership exceeds 5% and amendments are filed for material changes, including falling below 5%.

Summary

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 1 to their Schedule 13G regarding their beneficial ownership of Immunome Inc. common stock.
As of March 31, 2025, EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 4,079,415 shares, representing 4.7% of Immunome Inc.'s common stock.
EcoR1 Capital Fund Qualified, L.P. beneficially owns 3,847,477 shares, representing 4.4% of the common stock.
The percentages are calculated based on 86,950,655 shares of Common Stock outstanding on March 14, 2025, as reported in Immunome Inc.'s Form 10-K for the fiscal year ended December 31, 2024.
The filing indicates that the aggregate ownership by the reporting persons is now 5% or less of the class, implying a reduction from a previous stake that was above 5%.
The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant institutional investor's stake below the 5% threshold, which can be interpreted as a decrease in confidence or a strategic divestment.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders may view the reduction in a significant institutional stake as a potential negative signal regarding the company's future prospects or valuation.

Key Dates

Date	Description
2024-12-31	Fiscal year end for Immunome Inc. Form 10-K, which reported shares outstanding.
2025-03-14	Date on which 86,950,655 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-K.
2025-03-31	Date of event which requires filing of this statement (beneficial ownership snapshot date).
2025-05-15	Date of filing of the Schedule 13G Amendment No. 1.

Keywords

Immunome Inc., EcoR1 Capital, Oleg Nodelman, Schedule 13G, beneficial ownership, common stock, institutional investment, stake reduction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.